NASDAQ$ETON
Eton Pharmaceuticals Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2020.
Eton Pharmaceuticals reported revenue of $20,000 in the second quarter of 2020, primarily from Biorphen sales. The company's net loss for the quarter was $4.7 million, and they had cash and cash equivalents of $10.3 million as of June 30, 2020.
- Submitted two NDAs, including one with orphan designation.
- Made significant progress preparing for the expected launch of Alkindi Sprinkle.
- Expect to complete two more NDA submissions in the coming months.
- Plan to launch as many as six branded products before the end of 2021.
Headline financials
Revenue & EPS history
Eton · Revenue · Quarterly
$20K
Revenue by segment
Eton · $24.3M total across 1 segment · Q1 2026
- Product Sales and Royalties$24.3M—100.0%
Forward guidance
Eton expects to launch as many as six branded products before the end of 2021 and implement new targeting strategies and promotional campaigns in the third quarter that are expected to drive stronger sales in the second half of 2020.
Tailwinds
- Alkindi Sprinkle's NDA is under review by the FDA.
- Expects the FDA to meet the existing September 29, 2020 PDUFA date without any disruption from COVID-19 for Alkindi Sprinkle.
- Believes the Alkindi Sprinkle application is approvable and is working aggressively on launch preparation activities.
- Plans to implement new targeting strategies and promotional campaigns in the third quarter that are expected to drive stronger sales in the second half of 2020.
- Expects the vial product launch to significantly accelerate Biorphen adoption.
Headwinds
- Biorphen sales continue to be impacted by COVID-19.
- Hospital policies continue to restrict sales representatives from visiting with pharmacy directors and hospital staff.
- Study participant enrollment for ET-105 has been impacted by COVID-19.
- Received Complete Response Letter in March 2020 for ET-105 (Lamotrigine for Oral Suspension).
- EM-100's goal date was extended to September 15th due to a proprietary name change submission by its partner.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2020
+0.6%
Avg return
Earnings day
+2.3%
Avg return
5 days after
+1.3%
Avg return
30 days after
48%
15 / 31 earnings
Positive
+36.0%
Q2 2023
Best reaction
-14.1%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +7.5% | -4.7% | — | |
| Q1 2026 | -3.0% | +6.7% | +2.4% | |
| Q3 2025 | -11.4% | -8.8% | -15.0% | |
| Q2 2025 | +12.5% | +12.2% | +15.8% | |
| Q1 2025 | +0.4% | +14.6% | -16.2% | |
| Q4 2024 | -4.0% | -7.0% | -6.2% | |
| Q3 2024 | +9.2% | +3.2% | +25.2% | |
| Q2 2024 | +6.6% | +8.0% | +31.5% | |
| Q1 2024 | -7.8% | -2.4% | -3.0% | |
| Q4 2023 | -14.1% | -21.0% | -23.7% | |
| Q3 2023 | -13.7% | -16.6% | -19.1% | |
| Q2 2023 | +36.0% | +79.5% | +83.7% | |
| Q1 2023 | +2.8% | +2.6% | +10.3% | |
| Q4 2022 | +2.6% | +7.1% | -7.4% | |
| Q3 2022 | +18.5% | +20.9% | +22.8% | |
| Q2 2022 | -1.0% | -19.4% | -22.8% | |
| Q1 2022 | +1.3% | +6.5% | -4.9% | |
| Q4 2021 | +6.1% | +8.7% | -1.5% | |
| Q3 2021 | -3.4% | -9.2% | -20.7% | |
| Q2 2021 | -5.0% | -0.2% | +12.7% | |
| Q1 2021 | +5.2% | +7.5% | -13.4% | |
| Q4 2020 | -0.7% | -1.1% | +5.9% | |
| Q3 2020 | -1.5% | +2.9% | +19.9% | |
| Q2 2020 | -2.2% | +4.4% | +12.4% | |
| Q1 2020 | -9.2% | -10.3% | -1.1% | |
| Q4 2019 | -8.4% | -21.9% | -39.8% | |
| Q3 2019 | +1.9% | +2.3% | +9.2% | |
| Q2 2019 | +1.6% | -1.8% | -14.2% | |
| Q1 2019 | +3.2% | +12.2% | +5.9% | |
| Q4 2018 | -2.3% | +2.6% | -5.8% | |
| Q3 2018 | -8.1% | -4.8% | -3.2% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro